Overall Fundamental outlook

Business Operations:

Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic

Alkem Laboratories Limited, a pharmaceutical company, engages in the research and development, manufacture, and sale of pharmaceutical and nutraceutical products in India, the United States, and internationally. The company offers branded generics, generic drugs, active pharmaceutical ingredients, and biosimilars, and nutraceuticals in acute and chronic therapeutic areas comprising anti-infective, gastro-intestinal, pain/analgesic, anti-diabetic, neuro/central nervous system, gynecology, respiratory, dermatology, and cardiac diseases. It also provides vitamins, minerals, and nutrients, as well as mouth wash, shampoos, pregnancy detection kits, and condoms. The company was incorporated in 1973 and is headquartered in Mumbai, India.

Revenue projections:

Revenue projections for ALKEM
Revenue projections for ALKEM

ALKEM is projected to see a decline in revenue compared to last year, which could lead to investor caution. A drop in earnings is often viewed as a negative signal for profitability, making it more difficult for the company to maintain investor confidence in its financial health.

Financial Ratios:

currentRatio 2.76100
forwardPE 25.35926
debtToEquity 11.10600
earningsGrowth 0.04200
revenueGrowth 0.07100
grossMargins 0.62008
operatingMargins 0.08767
trailingEps 181.09000
forwardEps 213.95000

ALKEM's current ratio, being 2.761, demonstrates that the company has the liquidity necessary to service its short-term debt. With strong cash reserves and current assets, ALKEM is well-equipped to meet its immediate financial obligations without any difficulties.
ALKEM's Forward PE ratio suggests that the stock is priced appropriately in relation to its earnings. Not being overpriced, it offers room for growth, signaling potential upside for investors looking for a stock with reasonable valuation and growth potential.
Alkem Laboratories Limited's low Debt-to-Equity ratio shows the company avoids heavy reliance on debt. This balanced approach reduces financial risk, as it maintains a healthy equity position without excessive leverage, providing greater financial stability and flexibility.
ALKEM's forward EPS is higher than its trailing EPS, suggesting the company is expected to see an increase in profitability this year. This points to positive growth, indicating that ALKEM is projected to improve its financial performance compared to the previous year.

Price projections:

Price projections for ALKEM
Price projections for ALKEM

The price of ALKEM has often been situated close to the lower end of projections. This consistent trend may signal difficulties for the company in achieving investor expectations for future performance.

Recommendation changes over time:

Recommendations trend for ALKEM
Recommendations trend for ALKEM


Analysts have maintained a buy bias for ALKEM, which could prompt investors to consider the stock as a viable investment. With this positive outlook, ALKEM is positioned as an attractive option for those looking to park their money in a stable and potentially lucrative company.